Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2025)

Roivant Sciences' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $203.0 million for Q4 2025.

• Quarterly Cash from Financing Activities rose 119.47% year-over-year to $203.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$964.8 million (up 29.08% YoY) and the FY2026 annual result came in at $134.2 million, up 111.0% from the prior year.
• Cash from Financing Activities was $203.0 million for Q4 2025 at Roivant Sciences, up from $62.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $452.0 million in Q4 2023 and bottomed at -$1.0 billion in Q4 2024.
• A 5-year average of -$1.6 million and a median of $62.6 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 2931.66% — and 2024, when it tumbled 8935.31%.
• Roivant Sciences' Cash from Financing Activities stood at $305.7 million in 2021, then retreated by 5.43% to $289.1 million in 2022, then surged by 56.33% to $452.0 million in 2023, then slumped by 330.68% to -$1.0 billion in 2024, then surged by 119.47% to $203.0 million in 2025.
• Business Quant data shows ROIV's Cash from Financing Activities at $203.0 million in Q4 2025, $62.6 million in Q3 2025, and -$187.8 million in Q2 2025.